Summary
This network meta-analysis aimed to compare the efficacy of influenza vaccines of any valency for adults 60 years and older. It demonstrated efficacy associated with IIV3-HD and RIV vaccines in protecting older persons against LCI, and RIV vaccine may reduce all-cause mortality when compared with other vaccines, but the evidence is uncertain. However, differences in efficacy between these influenza vaccines remain uncertain with very low to moderate certainty of evidence.
Project Resources
- Journal article: https://ebm.bmj.com/content/early/2024/04/10/bmjebm-2023-112767.full
Funded By
- Canadian Institutes for Health Research/Drug Safety and Effectiveness Network (CIHR DSEN)
Principal Investigators
- Areti Angeliki Veroniki
Co-Investigators
- Sharon E. Straus
- Andrea C. Tricco
Collaborators
- Margarita Corry (Trinity College)
- Pamela Doyon-Plourde (PHAC)
- Kelly English (Arthritis Research Canada)*
- Ivan D. Florez (Universidad de Antioquia and McMaster University)
- Anabel Gil (PHAC)
- Brian Hutton (Ottawa Hospital Research Institute)
- Lorenzo Moja (University of Milan)
- Nasheed Moqueet (PHAC)
- Matthew Muller (St. Michael’s Hospital)
- Angela Sinilaite (PHAC)
- Winnie Siu (PHAC)
- Adrienne Stevens (PHAC)
- Juan J. Yepes-Nuñez (Universidad de los Andes)
KTP Project Staff
- Jasmeen Dourka
- Marco Ghassemi
- Paul A. Khan
- Menelaos Konstantinidis
- Dipika Neupane
- Vera Nincic
- Amanda Parker
- Reid Robson
- Charlene Soobiah
- Sai Surabi Thirugnanasampanthar
*Patient Partner: These individuals could be patients (an individual with a health condition), family members of a patient (e.g. parent, spouse, adult child or other close family member of a patient not capable of decision-making), caregivers (family, relative, friends or neighbours providing unpaid assistance to someone with a health condition/limitation), people with lived experience (those with first-hand experience of the topic of interest,), or members of the public at large.